South Korea’s AimedBio Invests in Inocras, Partners on WGS for Cancer Trials
The companies hope to find patients likely to respond to AimedBio’s antibody-drug conjugates.
Inocras and South Korean biopharma company AimedBio are partnering to integrate whole-genome sequencing data into development of antibody-drug conjugates (ADC) for cancer.
Aimed Bio is also making an equity investment in Inocras for an undisclosed amount.
Under the agreement, announced July 1, AimedBio will apply Inocras’ whole-genome sequencing (WGS), multiomics, and data analysis capabilities across its ADC clinical trials to support biomarker identification, patient selection, and target discovery.
The two companies also plan to explore joint commercial opportunities, connecting AimedBio’s precision drug screening business with Inocras’ diagnostic platform.
In a statement, the companies said they aim to accelerate clinical development and uncover new opportunities for precision drug discovery.
“This partnership reflects what we’ve believed from the start, that cancer whole genome data has a role beyond diagnosing cancer. It can directly shape how new treatments are developed and identify which patients are most likely to benefit,” Inocras CEO Jehee Suh said in a statement. Finding likely responders is especially important “as ADC development grows more competitive,” AimedBio CEO Nam-Gu Her added.
AimedBio is a spin-off from South Korea’s Samsung Medical Center. Inocras is headquartered in San Diego, with other offices in South Korea and Hong Kong.
The companies declined to disclose a specific number of patient samples that Inocras will process under the agreement.